The Toll-like family of immune receptors (TLRs) are critical for an efficient immune response to a variety of
microorganisms and other antigens that may cause pathology. Modulating immune responses by targeting TLRs therefore
has substantial therapeutic potential, and a number of TLR-based therapeutic strategies have been developed. Minimizing
the adverse effects that may result from the therapeutic manipulation of these signalling receptors nevertheless remains a
major challenge. Efficient responses via TLRs require the activity of the co-receptor CD14, which enhances TLR responses.
In an attempt to boost the immune response for therapeutic purposes, we have sought to target CD14 to achieve
TLR modulation. Here we discuss the design, activity and therapeutic development options of TLR-derived peptides that
interact with CD14 and enhance its co-receptor activity, thus amplifying TLR-mediated responses. This strategy represents
a promising alternative to current TLR-based therapies, as it has the potential to amplify responses to different
pathogens mediated by different TLRs by targeting the common TLR co-receptor, CD14.
Keywords: Immune response, Toll-like receptors, CD14, Toll-like receptor-based therapies, vaccines, peptides.
open access plus
Rights & PermissionsPrintExport